From survodutide titration to oral PCSK9 adherence and HF care models, AHA 2026 experts pointed to pharmacists as key to putting new data into practice.
|Articles|January 31, 2022
Daily Medication Pearl: Mesalamine (Apriso)
Author(s)Saro Arakelians, PharmD
Mesalamine (Apriso) is a locally acting aminosalicylate indicated to treat and prevent flare-ups of ulcerative colitis.
Advertisement
Medication Pearl of the Day: Mesalamine (Apriso)
Indication: Mesalamine (Apriso) is a locally acting aminosalicylate indicated for the maintenance of diarrhea, upper abdominal pain, nausea, nasopharyngitis, flu or flu-like remission of ulcerative colitis in adults.
Insight:
- Dosing: Four capsules once daily (1.5 g/day) in the morning with or without food. Do not co-administer with antacids.
- Dosage forms: Extended-release capsules 0.375 g.
- Adverse events: The most common adverse reactions (incidence ≥3%) are headache, diarrhea, upper abdominal pain, nausea, nasopharyngitis, flu or flu-like remission of ulcerative colitis in adults, illness, and sinusitis.
- Mechanism of action: The mechanism of action of mesalamine is unknown but appears to be local to the intestinal mucosa rather than systemic.
- Manufacturer: Catalent Pharma
Sources:
Advertisement
Related to this article
Christie Ballantyne, MD, says high extension enrollment and a single 20-mg daily dose are encouraging signs for patient adherence to oral enlicitide.
An ASRA-recognized quality improvement project draws attention to injectate reproducibility, offering a starting point for examining medication preparation and pharmacists’ role in safer pain procedures.
A meta-analysis presented at IDWeek 2026 found responses were stronger after chemotherapy but waned within a year, supporting a 2-dose strategy.
How should a factor XIa inhibitor be incorporated into secondary stroke prevention?
Inconsistent state immunization laws complicate pharmacy operations and limit patient access.
Pharmacists can strengthen opioid safety through individualized counseling, overdose prevention, and coordinated follow-up that keeps patients involved in treatment decisions.
OCEANIC-STROKE supports a potential additional antithrombotic approach for select patients after noncardioembolic stroke or high-risk TIA.
Advertisement
Advertisement
Trending on Pharmacy Times
1
AHA 2026: Pharmacists at the Center of Cardiometabolic Care
2
From Recognition to Prior Authorization: ATTR-CM Diagnosis Gaps
3
FDA Approves Perioperative Durvalumab Plus Enfortumab Vedotin-ejfv for MIBC
4
Glucose Monitoring: Timing Makes Every Reading Count
5